Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 60

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 60
---
 separate discrete information is available for evaluation by the chief operating decision maker (“CODM”), in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of identifying, developing and commercializing pharmaceutical products that target unmet needs in women's health. The CODM, who is the chief executive officer (“CEO”), manages and allocates resources to the operations of the Company on a consolidated basis. The Company’s measure of segment profit or loss is net loss. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Operating expenses are used to monitor budget versus actual results. The CODM does not review assets in evaluating the results of the Company, and therefore, such information is not presented. In addition, substantially all of the Company's revenue was generated in the United States and substantially all of the Company's long-lived assets reside in the United States. The following table summarizes the segment's financial information including the Company’s significant segment expenses:

26

Three Months EndedSeptember 30,Nine Months Ended September 30,2025202420252024Revenue:Royalty revenue$2,262 $41,691 $6,517 $73,431 Total revenue2,262 41,691 6,517 73,431 Segment operating expenses:Research and development:Direct program costs:Ovaprene1,458,054 1,940,537 4,270,154 7,103,894 Sildenafil Cream (1)417,543 (60,905)678,813 1,105,605 Other advanced clinical stage programs699,866 164,351 2,165,918 1,009,655 Phase 1 and Phase 1-ready clinical stage programs269,641 91,847 1,394,982 526,291 Preclinical stage programs2,111,045 554,677 4,878,104 3,232,899 Other development programs— 1,206 — 24,132 Contra-R&D expenses